Clinical Trial Update: Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update for henagliflozin in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Henagliflozin (henagliflozin)

Snippet

Sponsor: Sir Run Run Shaw Hospital | Conditions: Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease | Phase 4 | Status: UNKNOWN